Scientific Program

Conference Series Ltd invites all the participants across the globe to attend Cancer Diagnostics Conference & Expo Rome, Italy.

Day 1 :

OMICS International Cancer Diagnostics 2016 International Conference Keynote Speaker Diana Anderson photo
Biography:

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has an H index of 57, 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J.Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD

Abstract:

Detection tests have been developed for many cancers, but there is no single test to identify cancer in general. We have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes of 208 individuals: 20 melanoma, 34 colon cancer, 4 lung cancer patients 18 suspect melanoma, 28 polyposis, 10 COPD patients and 94 healthy volunteers. The natural logarithm of the Olive tail moment was plotted for exposure to UVA through different agar depths for each of the above groups and analysed using a repeated measures regression model. Response patterns for cancer patients formed a plateau after treating with UVA where intensity varied with different agar depths. In comparison, response patterns for healthy individuals returned towards control values and for pre/suspected cancers, were intermediate with less of a plateau. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic curves, of mean log Olive tail moments, for all cancers plus pre/suspected-cancer versus controls gave a value for the area under the curve of 0.87; for cancer versus pre/suspected-cancer plus controls the value was 0.89; and for cancer alone versus controls alone (excluding pre/suspected-cancer), the value was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable complementary measures. Evidence presented indicates that this modified assay shows promise as both a stand-alone test and as a possible adjunct to other investigative procedures, as part of detection programmes for a range of cancers.

Keynote Forum

Tibor Tot

Central Hospital Falun, Sweden

Keynote: Optimal breast cancer pathology 2016
OMICS International Cancer Diagnostics 2016 International Conference Keynote Speaker Tibor Tot photo
Biography:

Tibor Tot is an Associate Professor of Pathology at the University of Uppsala and Head of Laboratory Medicine Dalarna, Sweden. He is a Faculty Member of the Breast Pathology Arm of the European School of Pathology (ESP) and Scientific Director in the European School of Oncology Certificate of Competence in Breast Cancer program. He has published 6 textbooks, 20 book chapters and 80 journal articles mostly on radiological-pathological correlation of breast diseases. He is a Member of the European Working Group for Breast Cancer Screening Pathology and past Chair of the Working Group for Breast Pathology of the ESP.

Abstract:

The morphology of breast carcinoma is often very complex. Tumor characteristics which are detectable with microscopy, molecular phenotyping of tumors or gene sequencing are seemingly very different but a close relationship between them can be evidenced indicating the necessity of multi-parameter characterization of breast carcinomas for proper diagnosis and therapy. A European Breast Cancer Council working group published a manifesto considering optimal breast pathology in Europe based on sessions at European Breast Cancer Conference in Glasgow on 20 March 2014 and following discussion. The Manifesto sets out optimal technical and organizational requirements for a breast cancer pathology service, in the light of concerns about variability and lack of patient-centered focus. It is not a guideline about how pathology services should be performed. It is a call for all in the cancer community pathologists, oncologists, patient advocates, health administrators and policymakers to check that services are available that serves the needs of patients in a high quality, timely way. By stating the essential diagnostic and prognostic pathology services and listing the parameters, these services should provide, this Manifesto aims to set the optimal standards in morphological diagnosis of breast cancer. rn